Search, analyze & compare

My selected companies

Adjust valuation method
WatchlistNameTickerP/EP/SP/BEV/EbitdaROEROICRSISMA200DCFVolumeClosing price
-
Gritstone Oncology IncGRTS-0.039.300.33-0.38-201.94%-46.48%46.33$0.40$0.044,758,720$0.0322

Detail of Gritstone Oncology Inc

 
CEO
Dr. Andrew R. Allen BCh, BM, M.D., MA, MRCP, Ph.D.
Employees
231
Industry
Biotechnology
Sector
Healthcare
Market cap
$5M

Company details

Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing vaccine-based immunotherapy candidates against cancer and infectious diseases. Its primary product candidate is GRANITE, an individualized immunotherapy candidate, which is in Phase 2/3 clinical trials for the treatment of microsatellite stable colorectal cancers; and has completed Phase 1/2 clinical trials for treating solid tumors. The company is also developing SLATE, an off-the-shelf immunotherapy candidate, which is in Phase 2 clinical trials for the treatment of metastatic solid tumors. In addition, it develops CORAL, a COVID-19 vaccine program; and a therapeutic vaccine candidate that is in Phase 1 clinical trials designed to treat and cure human immunodeficiency virus (HIV) infection. Gritstone bio, Inc. has a strategic collaboration with bluebird bio, Inc.; collaboration agreement with Gilead Sciences, Inc.; and license agreement with Genevant Sciences GmbH. The company was formerly known as Gritstone Oncology, Inc. and changed its name to Gritstone bio, Inc. in May 2021. Gritstone bio, Inc. was incorporated in 2015 and is headquartered in Emeryville, California. On October 10, 2024, Gritstone bio, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

Revenue
Revenue (Rev)
$496,000.00
Gritstone Oncology Inc
GRTS • XNGS • US
$0.0322
-1.51 (-98.37%)
Stock vs Industry average
  • Industry average

Negative values are hidden from the graph.
Trailing annual dividend rate
$0.00
Payout ratio
0.00%
EPS
-$0.93
Margin profit
0.00%
52 week low
$0.0193
52 week high
$2.90
50-day simple moving average
$0.03
200-day simple moving average
$0.40
Percent held by insiders
1.91%
Percent held by institutions
29.03%
Dividend yield
0.00%

Change of shares

Cash vs Debt

Insider Trading

Comparison of selected companies

 
%
Price change
GRTS -98.37%
eps change
GRTS 0.00%